Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifirafenib + Mirdametinib in advanced solid tumors
NCT03905148Phase 1Completed
- Sponsor
- BeiGene
- Start
- May 2019
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of lifirafenib and mirdametinib in solid tumor (2 arms), sponsored by BeiGene. Primary endpoints: Adverse Events at 2 years, Dose-Limiting Toxicity at 2 years and 1 more. Started May 2019; status: completed.
02
Drugs
lifirafenibmirdametinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03905148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03905148.